AceLink is advancing a small-molecule treatment option for Fabry disease that could provide a more convenient alternative to ...

and then carefully construct an experiment to measure the catalytic turnovers of their test enzyme, β-galactosidase. Though many groups including Xie's had attempted to use fluorescence to study ...

Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (GLA), which leads to complex multisystemic involvement, with the majority of patients ...

It remains to be seen whether other enzyme-replacement therapies can duplicate its economic success. Fabry's disease is an X-linked disorder caused by a deficiency of α-galactosidase. The ...

Fabry Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future growth ...

GM1 gangliosidosis is a neurodegenerative disorder caused by an autosomal recessive deficiency of the enzyme ß-Galactosidase 1 (GLB1). This disorder affects approximately 1 in 100,000 newborns, with ...